🏛️ Verified NIH Record • Updated 2026-05-22

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis (NCT06046222)

A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of NS-229 in the Treatment of Eosinophilic Granulomatosis With Polyangiitis

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: NS Pharma, Inc.

🩺 Plain-English Summary (8th-Grade Level)

This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.

Who can join: Review the eligibility criteria below.

Location: National Jewish Health — Denver, Colorado

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (34 Sites)

Showing the first 25 of 34 sites.

  • National Jewish Health — Denver, Colorado
  • Mayo Clinic — Rochester, Minnesota
  • Cleveland Clinic — Cleveland, Ohio
  • The Ohio State University Wexner Medical Center — Columbus, Ohio
  • University of Pennsylvania — Philadelphia, Pennsylvania
  • Medical University of South Carolina — Charleston, South Carolina
  • Vanderbilt University Medical Center — Nashville, Tennessee
  • University of Alberta — Edmonton, Alberta
  • St Joseph's Healthcare Hamilton — Hamilton, Ontario
  • University of Toronto — Toronto, Ontario
  • CHU Nice — Nice,
  • Hopital Cochin — Paris,
  • Chu Rangueil — Toulouse,
  • Medius Kliniken gGmbh — Kirchheim unter Teck, Studienzentrale
  • Istituto Auxologico Italiano IRCCS — Milan,
  • Fondazione Policlinico Universitario Campus Bio-Medico — Roma,
  • Azienda Provinciale per i Servizi Sanitari Provincia Autonoma Trento — Trento,
  • Azienda Ospedaliera Universitaria Integrata Verona — Verona,
  • Chiba University Hospital — Chuo-ku, Chiba-shi, Chiba
  • Hospital of the University of Occupational and Environmental Health, Japan — Kitakyushu, Fukuoka
  • Hokkaido University Hospital — Sapporo, Hokkaido
  • NHO Sagamihara National Hospital — Sagamihara, Kanagawa
  • National Hospital Organization Yokohama Medical Center — Yokohama, Kanagawa
  • Tohoku University Hospital — Sendai, Miyagi
  • Osaka Habikino Medical Center — Habikino, Osaka

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Eosinophilic Granulomatosis With Polyangiitis

Explore by condition: All Eosinophilic Granulomatosis With Polyangiitis clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗